| Basics |
Evolus, Inc.
Evolus Inc is engaged in providing physicians and their patients with expanded choices in medical aesthetic treatments and procedures. Its product candidate is an injectable formulation of a 900 kDa Botulinum toxin Type A complex.
|
| IPO Date: |
February 5, 2018 |
| Sector: |
Healthcare |
| Industry: |
Drug Manufacturers |
| Market Cap: |
$444.02M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.36 | 3.11%
|
| Avg Daily Range (30 D): |
$0.17 | 2.47%
|
| Avg Daily Range (90 D): |
$0.16 | 2.38%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.61M |
| Avg Daily Volume (30 D): |
1.41M |
| Avg Daily Volume (90 D): |
1.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
108 |
| Avg Trade Size (Sh.) (30 D): |
96 |
| Avg Trade Size (Sh.) (90 D): |
100 |
| Institutional Trades |
| Total Inst.Trades: |
1,019 |
| Avg Inst. Trade: |
$1.37M |
| Avg Inst. Trade (30 D): |
$.91M |
| Avg Inst. Trade (90 D): |
$.95M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.14M |
| Avg Closing Trade (30 D): |
$.95M |
| Avg Closing Trade (90 D): |
$.99M |
| Avg Closing Volume: |
98.25K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.9
|
$-.24
|
$-.27
|
|
Diluted EPS
|
$-.9
|
$-.24
|
$-.27
|
|
Revenue
|
$ 285.82M
|
$ 68.97M
|
$ 69.39M
|
|
Gross Profit
|
$ 190.45M
|
$ 45.84M
|
$ 45.32M
|
|
Net Income / Loss
|
$ -58.56M
|
$ -15.74M
|
$ -17.14M
|
|
Operating Income / Loss
|
$ -39.2M
|
$ -11.5M
|
$ -10.21M
|
|
Cost of Revenue
|
$ 95.37M
|
$ 23.13M
|
$ 24.07M
|
|
Net Cash Flow
|
$ -41.51M
|
$ -18.22M
|
$ -6.16M
|
|
PE Ratio
|
|
|
|
|
|
|
